These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 8910622)

  • 1. Preoperative value of CA 125 as a reflection of tumor grade in epithelial ovarian cancer.
    But I; Gorisek B
    Gynecol Oncol; 1996 Nov; 63(2):166-72. PubMed ID: 8910622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship of preoperative serum CA-125 to survival in epithelial ovarian carcinoma.
    Geisler JP; Miller GA; Lee TH; Harwood RM; Wiemann MC; Geisler HE
    J Reprod Med; 1996 Mar; 41(3):140-2. PubMed ID: 8778409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer.
    Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
    Acta Obstet Gynecol Scand; 2008; 87(11):1136-42. PubMed ID: 18951217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic importance of preoperative CA-125 in International Federation of Gynecology and Obstetrics stage I epithelial ovarian cancer: an Australian multicenter study.
    Paramasivam S; Tripcony L; Crandon A; Quinn M; Hammond I; Marsden D; Proietto A; Davy M; Carter J; Nicklin J; Perrin L; Obermair A
    J Clin Oncol; 2005 Sep; 23(25):5938-42. PubMed ID: 16087942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A retrospective study of preoperative CA 125 levels in 82 patients with ovarian cancer.
    Rossi AC; Di Vagno G; Cormio G; Cazzolla A; Stefanelli S; D'Elia E; Selvaggi L
    Arch Gynecol Obstet; 2004 May; 269(4):263-5. PubMed ID: 14745561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study.
    Gadducci A; Zola P; Landoni F; Maggino T; Sartori E; Bergamino T; Cristofani R
    Gynecol Oncol; 1995 Jul; 58(1):42-7. PubMed ID: 7789889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COX-2 and preoperative CA-125 level are strongly correlated with survival and clinical responsiveness to chemotherapy in ovarian cancer.
    Raspollini MR; Amunni G; Villanucci A; Boddi V; Taddei GL
    Acta Obstet Gynecol Scand; 2006; 85(4):493-8. PubMed ID: 16612714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?
    Ayhan A; Guven S; Guven ES; Kucukali T
    Acta Obstet Gynecol Scand; 2007; 86(4):484-90. PubMed ID: 17486473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
    Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
    Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of the tumour markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma.
    Hasholzner U; Baumgartner L; Stieber P; Meier W; Hofmann K; Fateh-Moghadam A
    Anticancer Res; 1994; 14(6B):2743-6. PubMed ID: 7532929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of serum CA-125 levels in early-stage epithelial ovarian cancer on preoperative CT and MRI.
    Kim HS; Kim JW; Cho JY; Chung HH; Park NH; Song YS; Kim SH; Kang SB
    Eur J Surg Oncol; 2009 Aug; 35(8):870-6. PubMed ID: 19179039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
    Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
    Onkologie; 2008 Jun; 31(6):315-20. PubMed ID: 18547972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TPS and CA 125 levels in serum, cyst fluid and ascites of patients with epithelial ovarian neoplasms.
    Harłozinska A; Sedlaczek P; Van Dalen A; Rozdolski K; Einarsson R
    Anticancer Res; 1997; 17(6D):4473-8. PubMed ID: 9494553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
    Riisbro R; Stephens RW; Brünner N; Christensen IJ; Nielsen HJ; Heilmann L; von Tempelhoff GF
    Gynecol Oncol; 2001 Sep; 82(3):523-31. PubMed ID: 11520150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of serum CA125 with stage, grade and survival of patients with epithelial ovarian cancer at a single centre.
    Osman N; O'Leary N; Mulcahy E; Barrett N; Wallis F; Hickey K; Gupta R
    Ir Med J; 2008 Sep; 101(8):245-7. PubMed ID: 18990955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA125) in patients with epithelial ovarian cancer.
    Peters-Engl C; Medl M; Ogris E; Leodolter S
    Anticancer Res; 1995; 15(6B):2727-30. PubMed ID: 8669854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prognostic value of early normalization of CA 125 during chemotherapy in stages III and IV ovarian tumors].
    Ferrero JM; Largillier R; Ramaioli A; Heudier P; Teissier E; Namer M
    Bull Cancer; 1997 Jul; 84(7):722-8. PubMed ID: 9339198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between postoperative decline of serum CA 125 levels and size of residual disease after initial surgery in patients with advanced ovarian cancer: a CTF study.
    Gadducci A; Landoni F; Maggino T; Sartori E; Zola P; Fanucchi A
    Gynecol Oncol; 1996 Nov; 63(2):234-7. PubMed ID: 8910633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can optimal primary cytoreduction be predicted in advanced stage epithelial ovarian cancer? Role of preoperative serum CA-125 level.
    Obeidat B; Latimer J; Crawford R
    Gynecol Obstet Invest; 2004; 57(3):153-6. PubMed ID: 14726621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete cytoreduction: is epithelial ovarian cancer confined to the pelvis biologically different from bulky abdominal disease?
    Naik R; Nordin A; Cross PA; Hemming D; de Barros Lopes A; Monaghan JM
    Gynecol Oncol; 2000 Aug; 78(2):176-80. PubMed ID: 10926799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.